E-Newsletter - May 2017
Alliance at asco 2017
The 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO) will convene in Chicago June 2-6, bringing together more than 30,000 oncology professionals from around the world. This year's meeting theme is "Making a Difference in Cancer Care with You." Studies spanning the spectrum of cancer prevention an d care, from immunotherapy and precision medicine to survivorship, will be highlighted.
Each year, ASCO attendees learn from leading-edge scientific presentations, including papers and talks from Alliance researchers, as well as thousands of scientific abstracts and research news developments. At this year's conference, Alliance scientists will present more than 25 studies, sharing the latest findings on breast cancer, brain cancer, hematologic cancers, and gastric cancer, along with cancer control research. The Alliance will be well-represented with dozens of researchers participating on panels, discussing new research and giving poster presentations.
Join the Twitter conversation at #ASCO17 and please include @ALLIANCE_org
Here's a snapshot of studies that Alliance researchers will be presenting:
Breast Cancer
Evaluating the addition of bevacizumab (Bev) to endocrine therapy as first-line treatment for hormone-receptor positive (HR+)/HER2-negative advanced breast cancer (ABC): Pooled-analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials
Presenter: Miguel Martin
Study #: CALGB 40503
Abstract #: 1012 | Poster and Poster Discussion Se ssion | Poster
June 4, 2017, 8 am to 11:30 am (Hall A) and 4:45 pm to 6 pm (Hall B1)
Updated results from the phase III ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L) or their combination (L+T) in the adjuvant treatment of HER2-positive early breast cancer
Presenter: Alvaro Moreno-Aspitia
Study #: NCCTG N063D
Abstract #: 502 | Hall D2 | Oral Abstract Session | Oral
June 5, 2017, 9:45 am to 12:45 pm
Central Nervous System Tumors
NCCTG N1174: Phase I/comp arative randomized phase (Ph) II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma (GBM) (Alliance)
Presenter: Evanthia Galanis
Study #: NCCTG N1174
Abstract #2023 | S404 | Poster Discussion Session | Poster
June 5, 2017, 4:45 pm to 6 pm
Chronic Lymphocytic Leukemia (CLL)
A genetic risk-stratified, randomized phase 2 intergroup study of fludarabine/antibody combinations in symptomatic, untreated chronic lymphocytic leukemia (CLL): Results from Cancer and Leukemia Group B (CALGB) 10404 (Alliance)
Presenter: Amy S. Ruppert
Study #: CALGB 10404
Abstract #: 7503 | S100bc | Oral Abstract Session | Oral
June 3, 2017, 3 pm to 6 pm
Gastrointestinal Cancer
Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration
Presenter: Qian Shi
Study #: IDEA/CALGB 8 0702
Abstract # LBA1 | Hall B1 | Plenary Session including Science of Oncology Award and Lecture | Oral
June 4, 2017, 1 pm to 4 pm
Nut consumption and survival in stage III colon cancer patients: Results from CALGB 89803 (Alliance)
Presenter: Temidayo Fadelu
Study #: CALGB 89803
Abstract # 3517 Poster and Poster Discussion Session (Board #140) | Poster
June 3, 2017, 8 am to 11:30 am (Hall A) and 1:15 pm to 2:30 pm (Arie Crown Theater)
Learn more about the results
Statistical modeling of CALGB 80405 (Alliance) to identify influential factors in metastatic colorectal cancer (CRC) dependent on primary tumor side
Presenter: David Swanson
Study #: CALGB 80405
Abstract #: 3528 | Hall A | Poster Session (Board #151) | Poster
June 3, 2017, 8 am to 11:30 am
Impact of consensus molecular subtyping (CMS) on overall survival (OS) and progression free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CAL GB/SWOG 80405 (Alliance)
Presenter: Heinz-Josef Lenz
Study #: CALGB 80405
Abstract #: 3511 | E354b | Clinical Science Symposium
June 4, 2017, 9:45 am to 11:45 am
Primary (1°) tumor location as an independent prognostic marker from molecular features for overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB / SWOG 80405 (Alliance)
Presenter: Alan Venook
Study #: CALGB 80405
Abstract #: 3503 | Hall D2 | Oral Abstract Session | Oral
June 5, 2017, 3 pm to 6 pm
Somatic DNA mutations, MSI status, mutational load (ML): Association with overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC) of CALGB/SWOG 80405 (Alliance)
Presenter: Federico Innocenti
Study #: CALGB 80405
Abstract #: 3504 | Hall D2 | Oral Abstract Session | Oral
June 5, 2017, 3 pm to 6 pm
Association of immune markers and Immunoscore with survival of stage III colon carcinoma (CC) patients (pts) treated with adjuvant FOLFOX: NCCTG N0147 (Alliance)
Presenter: Frank A. Sinicrope
Study #: NCCTG N0147
Abstract #: 3579 | Hall A | Poster Session (Board #202) | Poster
June 3, 2017, 8 am to 11:30 am
Genetic correlates of therapeutic toxicities of stage III colon carcinoma patients treated with adjuvant FOLFOX+/-cetuximab (NCCTG N0147, Alliance)
Presenter: Polly A. Newcomb
Study #: NCCTG N0147
Abstract #: 3604 | Hall A | Poster Session (Board #227) | Poster
June 3, 2017, 8 am to 11:30 am
Analysis of serum v itamin D levels and prognosis in stage III colon carcinoma patients treated with adjuvant FOLFOX+/- cetuximab chemotherapy: NCCTG N0147 (Alliance)
Presenter: Frank A. Sinicrope
Study #: NCCTG N0147
Abstract #: 3516 | Poster and Poster Discussion Session (Board #139) | Poster
June 3, 2017, 8 am to 11:30 am (Hall A) and 1:15 pm to 2:30 pm (Arie Crown Theater)
Randomized trial of FOLFOX alone or combined with atezolizumab as adjuvant therapy for patients with stage III colon cancer and deficient DNA mismatch repair or microsatellite instability (ATOMIC, Alliance A021502)
Presenter: Frank A. Sinicrope
Study #: Alliance A021502
Abstract #: TPS3630 | Hall A | Poster Session (Board #247a) | Poster
June 3, 2017, 8 am to 11:30 am
Alliance for Clinical Trials in Oncology trial A021501: Preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas
Presenter: Matthew H. G. Katz
Study #: Alliance A021501
Abstract # TPS4151 | Hall A | Poster Session (Board #133a) | Poster
June 3, 2017, 8 am to 11:30 am
Genitourinary Cancer
Serum androgens and survival in metastatic castration resistant prostate cancer (mCRPC) patients treated with docetaxel and prednisone: Results from CALGB 90401 (Alliance)
Presenter: Charles J. Ryan
Study #: CALGB 90401
Abstract #: 5067 | Hall A | Poster Session (Board #141) | Poster
June 5, 2017, 1:15 pm to 4:45 pm
Association of on-treatment plasma HGF levels with overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (INF) +/- bevacizumab (BEV): Results from CALGB 90206 (Alliance)
Presenter: Daniel J. George
Study #: CALGB 90206
Abstract # 4522 | Hall A | Poster Discussion Session (Board #200) | Poster
June 4, 2017, 8 am to 11:30 am
Health Services Research, Clinical Informatics and Quality of Care
Understanding the non-curative potential of palliative chemotherapy: Do patients hear what they want to hear?
Presenter: Andrea Catherine Enzinger
Study #: NCT02282722
Abstract #: 6575 | Hall A | Poster Session | Poster
June 5, 2017, 1:15 pm to 4:45 pm
Multiple Myeloma
CALGB/ECOG 100104 (Alliance) study: Lenalidomide (LEN) vs placebo (PBO) maintenance (maint) after stem cell transplant (SCT) for patients (pts) with multiple myeloma-Overall survival (OS) and progression-free survival (PFS) adjusted for treatment (tx) crossover (XO)
Presenter: Philip L. McCarthy
Study #: CALGB 100104
Abstract #: 8037 | Hall A | Poster Session (Board #363) | Poster
June 5, 2017, 8 am to 11:30 am
Patient and Survivor Care
American Cancer Society (ACS) Nutrition and Physical Activity Guidelines after colon cancer diagnosis and disease-free (DFS), recurrence-free (RFS), and overall survival (OS) in CALGB 89803 (Alliance)
Presenter: Erin Van Blarigan
Study #: CALGB 89803
Abstract # 10006 | S102 | Oral Abstract Session | Poster
June 3, 2017, 3 pm to 6 pm
Learn more about the results
Comparative nocebo effects in older patients enrolled in cancer therapeutic trials: Observations from a 446-patient cohort-NCCTG 97-24-51 and ACOSOG Z9001 (Alliance A151602)
Presenter: Jennifer Le-Rademacher and Jared C. Foster
Study #: Alliance A151602, ACOSOG Z9001, NCCTG 97-24-51
Abstract #e21545 (Publication-only; online only)
Sarcoma
A multi-center phase II study of nivolumab +/- ipilimumab for patients with metastatic sarcoma (Alliance A091401)
Presenter: Sandra P. D'Angelo
Study #: Alliance A091401
Abstract #: 11007 | S100bc | Oral Abstract Session | Oral
June 2, 2017, 3 pm to 6 pm
ALLIANCE FOUNDATION TRIALS (AFT)
Health Services Research, Clinical Informatics and Quality of Care
Comparison of comorbidity measures to predict postoperative lung cancer survival in the National Cancer Database (AFT-03)
Presenter: Melisa L. Wong
Study #: AFT-03
Abstract #6519 | Poster and Poster Discussion Session (Board #341) | Poster
June 5, 2017,1:15 pm to 4:4 5 pm (Hall A) and 4:45 pm to 6 pm (S504)
Asymptomatic distant recurrence detection and survival in early stage breast cancer: A nationally representative study
Presenter: Jessica R. Schumacher
Study #: PCORI AFT-01
Abstract #: 6520 | Poster and Poster Discussion Session (Board #342) | Poster
June 5, 2017, 1:15 pm to 4:45 pm (Hall A) and 4:45 pm to 6 pm (S504)
Lung Cancer
Tolerability of veliparib (V) in combination with carboplatin (C)/paclitaxel (P): Based chemoradiotherapy (CRT) in subjects with stage III non-small cell lung cancer (NSCLC)
Presenter: David E. Kozono
Study #: PCORI AFT-07 | Poster Session (Board #282) | Poster
Abstract #: 8546
June 3, 2017, 8 am to 11:30 am
Patient and Survivor Care
Impact of intensity of post-treatment surveillance on survival in colorectal cancer
Presenter: Rebecca A Snyder
Study #: PCORI AFT 02
Abstract #: 10016 | Poster and Poster Discussion Session (Board #5) | Poster
June 3, 2017, 1:15 pm to 4:445 pm (Hall A) and 4:45 pm to 6 pm (S404)
